United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 15 mg - lansoprazole delayed-release capsules, usp are indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14)]. triple therapy: lansoprazole/amoxicillin/clarithromycin lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole/amoxicillin lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to cl

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole delayed-release capsules are indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer. [see clinical studies (14)] triple therapy: lansoprazole delayed-release capsules /amoxicillin /clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. [see clinical studies (14) ]  please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole delayed-release capsules /amoxicillin  dual therapy: lansoprazole delayed-release capsules /amoxicillinlansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated for the treatment of patients with h. pylori infection a

United States - English - NLM (National Library of Medicine)

a-s medication solutions - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole delayed-release capsules are indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14)]. triple therapy: lansoprazole delayed-release capsules/amoxicillin/clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole delayed-release capsules/amoxicillin lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duod

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - methotrexate 20 mg/ml - injection with diluent - 20 mg/ml - active: methotrexate 20 mg/ml excipient: sodium chloride sodium hydroxide water for injection - - active rheumatoid arthritis in adult patients where treatment with disease modifying antirheumatic drugs (dmards) is indicated. - polyarthritic forms of severe, active juvenile idiopathic arthritis (jia) when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate - severe forms of psoriasis vulgaris, particularly of the plaque type, which cannot be sufficiently treated with conventional therapy such as phototherapy, puva, and retinoids, and severe psoriatic arthritis.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methotrexate 25 mg/ml (as methotrexate sodium) - solution for injection - 7.5 mg/0.3ml - active: methotrexate 25 mg/ml (as methotrexate sodium) excipient: sodium chloride sodium hydroxide water for injection - methotrexate may be of value in the symptomatic control of server, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.

Canada - English - Health Canada

teva canada limited - methotrexate (methotrexate sodium) - solution - 25mg - methotrexate (methotrexate sodium) 25mg - antineoplastic agents

Canada - English - Health Canada

medexus pharmaceuticals inc. - methotrexate (methotrexate sodium) - solution - 12.5mg - methotrexate (methotrexate sodium) 12.5mg - antineoplastic agents

Canada - English - Health Canada

medexus pharmaceuticals inc. - methotrexate (methotrexate sodium) - solution - 17.5mg - methotrexate (methotrexate sodium) 17.5mg - antineoplastic agents

Canada - English - Health Canada

medexus pharmaceuticals inc. - methotrexate (methotrexate sodium) - solution - 22.5mg - methotrexate (methotrexate sodium) 22.5mg - antineoplastic agents

Canada - English - Health Canada

medexus inc - methotrexate (methotrexate sodium) - solution - 7.5mg - methotrexate (methotrexate sodium) 7.5mg - antineoplastic agents